Skip Nav Destination
            
    
            
 
    
    
        
            
                
                    
                        
                        
                            
                        
                    
                
                    
                    
                        
                    
                
                
                    
                        
                        
                            
                        
                    
            
        
    
    
    
        
        
        
    
        
 
    
        
    
    
        
            
        
        
    
        
    
    
    
 
    
                
                    
            
    
        
    
    
                    
        
        
        Hydroxyurea for SCA in Africa: no malaria harm
        
        
            
        
    
        
    
            
                
            
    
    
    
        
        
     
    
                    
        
        
        Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
                     
    
                    
        
                    
        
        Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
                    
        
                    
                
            
    
    
    
        
        
     
    
                    
                    
                
            
    
    
    
        
        
     
    
                     
    
                    
                    
                
            
    
    
    
        
        
     
    
                    
                    
        
        Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2
        
        
            
        
    
        
                
            
    
    
    
        
        
     
    
                     
    
 
    
            
    
        
    
         
 
    
    
        
    
            
    
        
    
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
        
    
    
    
            
        
 
    
    
 
    
    
        
    
    
    
            
        
            
    
        
        
    
             
            
             
            
             
        
    
 
    
    
 
    
    
        
    
    
    
            
    
                    
 
    
    
 
    
    
 
    
    
    
    
        
    Issue Archive
December 14 2017
    
    
Table of Contents
INSIDE BLOOD COMMENTARIES
INSIDE BLOOD COMMENTARY
                    
        
        Hydroxyurea for SCA in Africa: no malaria harm
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
    
            PLENARY PAPER
CLINICAL TRIALS AND OBSERVATIONS
                    
        
        Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Robert O. Opoka,Christopher M. Ndugwa,Teresa S. Latham,Adam Lane,Heather A. Hume,Phillip Kasirye,James S. Hodges,Russell E. Ware,Chandy C. John
            
        
    
            REVIEW ARTICLE
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
        
        Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Hervé Avet-Loiseau,Nizar J. Bahlis,Wee-Joo Chng,Tamas Masszi,Luisa Viterbo,Ludek Pour,Peter Ganly,Antonio Palumbo,Michele Cavo,Christian Langer,Andrzej Pluta,Arnon Nagler,Shaji Kumar,Dina Ben-Yehuda,S. Vincent Rajkumar,Jesus San-Miguel,Deborah Berg,Jianchang Lin,Helgi van de Velde,Dixie-Lee Esseltine,Alessandra di Bacco,Philippe Moreau,Paul G. Richardson
            
        
    
            HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia
            Brenton G. Mar,S. Haihua Chu,Josephine D. Kahn,Andrei V. Krivtsov,Richard Koche,Cecilia A. Castellano,Jacob L. Kotlier,Rebecca L. Zon,Marie E. McConkey,Jonathan Chabon,Ryan Chappell,Peter V. Grauman,James J. Hsieh,Scott A. Armstrong,Benjamin L. Ebert
            
        
    
            MYELOID NEOPLASIA
Gene expression and risk of leukemic transformation in myelodysplasia
            Yusuke Shiozawa,Luca Malcovati,Anna Gallì,Andrea Pellagatti,Mohsen Karimi,Aiko Sato-Otsubo,Yusuke Sato,Hiromichi Suzuki,Tetsuichi Yoshizato,Kenichi Yoshida,Yuichi Shiraishi,Kenichi Chiba,Hideki Makishima,Jacqueline Boultwood,Eva Hellström-Lindberg,Satoru Miyano,Mario Cazzola,Seishi Ogawa
            
        
    
            RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Cytoprotective activated protein C averts Nlrp3 inflammasome–induced ischemia-reperfusion injury via mTORC1 inhibition
            Sumra Nazir,Ihsan Gadi,Moh’d Mohanad Al-Dabet,Ahmed Elwakiel,Shrey Kohli,Sanchita Ghosh,Jayakumar Manoharan,Satish Ranjan,Fabian Bock,Ruediger C. Braun-Dullaeus,Charles T. Esmon,Tobias B. Huber,Eric Camerer,Chris Dockendorff,John H. Griffin,Berend Isermann,Khurrum Shahzad
            
        
    
            TRANSPLANTATION
        
        Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2
        
        
            
        
                    
                        Clinical Trials & Observations
                    
        
            
    
        
            Hasan Hashem,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Ashish R. Kumar,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Ingo Müller,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Florian Babor,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Robbert Bredius,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Jignesh Dalal,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Amy P. Hsu,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Steven M. Holland,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Dennis D. Hickstein,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Stephen Jolles,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Robert Krance,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Ghadir Sasa,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Mervi Taskinen,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Minna Koskenvuo,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Janna Saarela,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Joris van Montfrans,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Keith Wilson,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Barbara Bosch,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Leen Moens,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Michael Hershfield,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation,Isabelle Meyts,on behalf of the Deficiency of Adenosine Deaminase Type 2 Foundation
            
        
    
            BLOOD WORK
- 
        
            Cover Image
        
        
Cover Image
            A 5-μm-thick left ventricle cross-cryosection obtained 24 hours after reperfusion and stained by triphenyltetrazolium chloride solution (TTC). The pale region that fails to stain (TTC-negative region) represents nonviable infarcted myocardium. Constitutively active Nlrp3A350V abolishes the protective effect of activated protein C in myocardial ischemia reperfusion injury. See the article by Nazir et al on page 2664.
 - PDF Icon Front MatterFront Matter
 - PDF Icon Table of ContentsTable of Contents
 - PDF Icon Back MatterBack Matter
 - PDF Icon Editorial BoardEditorial Board
 
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
                    
